{"entity":{"id":"map2k7","kind":"target","name":"MAP2K7","aka":["mitogen-activated protein kinase kinase 7","Dual specificity mitogen-activated protein kinase kinase 7","MKK7","Jnkk2","SAPKK4","PRKMK7"],"tldr":"MAP2K7 is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response.","summary":"Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signalling pathway. With MAP2K4/MKK4, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3.\n\nCIViC holds 4 clinical evidence items and 0 assertions across 3 variants, naming Palbociclib, Tamoxifen and Fulvestrant. IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Stomach Adenocarcinoma.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:6847","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6847"},{"label":"UniProt O14733","url":"https://www.uniprot.org/uniprotkb/O14733/entry"},{"label":"NCBI Gene 5609","url":"https://www.ncbi.nlm.nih.gov/gene/5609"},{"label":"Ensembl ENSG00000076984","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000076984"}],"tags":["cancer-genes-wave"],"related":["civic","intogen"],"cancers":["lung-cancer","gastric","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 4 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"MAP2K7","role":["drug-target","tumour-suppressor","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:6847","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6847","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt O14733","url":"https://www.uniprot.org/uniprotkb/O14733/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene MAP2K7","url":"https://civicdb.org/features/4546","note":"4 evidence items, 0 assertions, 3 variants; diseases: Oestrogen Receptor-positive Breast Cancer, Lung Cancer (GraphQL API, CC0)"},{"label":"IntOGen MAP2K7","url":"https://www.intogen.org/search?gene=MAP2K7","note":"driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0"}],"hgnc":"HGNC:6847","ensembl":"ENSG00000076984","uniprot":"O14733","entrez":"5609","biology":"Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Essential component of the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signalling pathway. With MAP2K4/MKK4, is the one of the only known kinase to directly activate the stress-activated protein kinase/c-Jun N-terminal kinases MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they differ in their preference for the phosphorylation site in the Thr-Pro-Tyr motif. MAP2K4/MKK4 shows preference for phosphorylation of the Tyr residue and MAP2K7/MKK7 for the Thr residue. The monophosphorylation of JNKs on the Thr residue is sufficient to increase JNK activity indicating that MAP2K7/MKK7 is important to trigger JNK activity, while the additional phosphorylation of the Tyr residue by MAP2K4/MKK4 ensures optimal JNK activation. Location: Nucleus; Cytoplasm (UniProt). Locus 19p13.2 (HGNC).","whereFound":["Lung cancer: CIViC evidence names this disease","Gastric & gastro-oesophageal junction cancer: IntOGen driver in 1 cohort (STAD)","HR-positive / HER2-negative breast cancer: CIViC evidence names this disease"],"targetClass":"kinase","prevalence":[]},"route":"/targets/map2k7/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"},{"id":"intogen","kind":"collection","name":"IntOGen","route":"/collections/intogen/"}],"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}]}}